GHRH Analog · FDA-Approved · Protocol Guide
Tesamorelin: The Complete Guide You Have Been Looking For
No marketing hype. No protocol myths. What the clinical evidence actually says about the only GHRH analog with Phase III data and an FDA approval.
FDA Status
FDA-Approved (Egrifta, 2010)
Pharmacy
Optimal Balance Pharmacy (503A licensed)
Medical Service
RxPepsDirect, physician-supervised
Access
33 U.S. States
Our promise: This guide tells you what tesamorelin cannot do as clearly as what it can. We include non-response rates, reversibility data, and side effect frequencies that other sources skip. If a claim is not backed by clinical evidence, we say so.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 18, 2026.Section 01
What Tesamorelin Actually Is
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland and triggers the natural, pulsatile release of growth hormone. It does not inject GH directly. That matters because pulsatile release preserves your body's feedback mechanisms, unlike exogenous HGH which bypasses them entirely.
Tesamorelin was FDA-approved in November 2010 under the brand name Egrifta (NDA 22-505) for one specific indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That Phase III clinical program produced some of the most robust visceral fat reduction data available for any peptide, including a 15 to 18 percent reduction in visceral adipose tissue (VAT) after 26 weeks at 2 mg per day.
15 to 18%
Visceral fat reduction at 26 weeks in Phase III trials
44
Amino acids in the tesamorelin molecule
2010
FDA approval year. 15+ years of human safety data
Section 02
Who It Is Actually For
Off-label, tesamorelin is used across four consumer profiles with meaningfully different goals. Understanding which profile fits you determines whether tesamorelin is the right choice, and what realistic success looks like for you.
| Profile | Primary Goal | Fit |
|---|---|---|
| Metabolic Optimizer (Male, 35 to 55, often on TRT) | Visceral fat reduction, body recomposition, IGF-1 optimization | Excellent |
| Anti-Aging Biohacker (Mixed gender, 45 to 65) | Longevity protocol, skin quality, sleep improvement, injury recovery | Strong |
| Performance Athlete (Male, 25 to 40, bodybuilding focus) | Fat loss during cut, lean mass preservation | Moderate |
| Aesthetic-Only Goals (Primary goal is visible belly fat) | External subcutaneous fat reduction | Poor Fit |
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
Profile
Primary Goal
Fit
Section 03
How It Works
Tesamorelin binds to GHRH receptors in the anterior pituitary gland and stimulates the natural, pulsatile release of growth hormone. GH then triggers the liver to produce insulin-like growth factor-1 (IGF-1), which drives the downstream metabolic effects, most notably lipolysis (fat breakdown) in visceral adipose tissue.
The mechanism differs critically from exogenous HGH. Because tesamorelin stimulates your own pituitary to release GH naturally, the release remains pulsatile and feedback-regulated. Your body's somatostatin system still applies the brakes. That is why tesamorelin's side effect profile is significantly more favorable than synthetic HGH, and why IGF-1 levels typically stay within physiological ranges rather than spiking to supraphysiological levels.
Section 04
Realistic Expectations, Honestly
This is the section most guides skip. The community's biggest frustration with tesamorelin is calibration failure: expecting results in 4 weeks when the molecule requires 3 to 6 months. We are going to set the record straight.
The Timeline That Actually Matches Clinical Data
Early Adaptation
Some users notice improved sleep quality and mild water retention. No measurable fat changes. Any vendor claiming visible results in 1 to 2 weeks is overstating the evidence.
IGF-1 Response
IGF-1 levels should be rising measurably. This is your first lab confirmation that the compound is working. Subcutaneous appearance is unlikely to change yet. Do not assess effectiveness at this stage.
Metabolic Shift
Some users begin noticing waistline changes, particularly those with significant baseline visceral fat. Triglyceride and liver enzyme improvements may appear in labs. Skin quality improvements frequently reported at this stage.
Minimum Assessment Point
First meaningful assessment of effectiveness. Clinical trials show measurable VAT reduction appearing between 8 and 16 weeks. If no IGF-1 response or subjective change by week 12, discuss with your RxPepsDirect physician before continuing.
Full Clinical Effect
Phase III data shows peak VAT reduction at 26 weeks. The 15 to 18 percent visceral fat reduction number comes from this timepoint. This is the minimum timeframe to fully evaluate your response.
Section 05
Dosing Protocol
The FDA-approved dose is 2 mg subcutaneously once daily. The dose is not weight-based. The Phase III trials used a fixed dose across the entire participant population. Multiple sources in the community suggest weight-adjusted dosing calculators, but these have no clinical basis.
| Context | Dose | Timing | Evidence Basis |
|---|---|---|---|
| FDA-Approved Protocol | 2 mg per day | Once daily, any time | Phase III RCT |
| RxPepsDirect Clinical Protocol | 2 mg per day (matches FDA), or 0.6 mg starting titration | Bedtime preferred (aligns with natural GH pulsatility) | Evidence-Based |
| Telehealth Reduced-Dose (common in some clinics) | 0.5 to 1 mg per day | Varies | Community Derived |
| Weight-Based Calculators | Variable formulas | Various | No Clinical Basis |
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Context
Dose
Timing
Evidence Basis
Titration Start (RxPepsDirect Standard)
Draw to the 20-unit mark on a U-100 insulin syringe
20 units = 0.2 mL = 0.6 mg
Daily subcutaneous injection into abdominal fat. Used for weeks 1 to 4 before assessing IGF-1 and considering dose escalation.
FDA-Approved Full Dose
Volume varies by vial concentration
2 mg per day
The Phase III protocol dose. Used when IGF-1 response guidance supports escalation, with physician approval.
Injection Site Guidance
Inject subcutaneously into abdominal fat. Rotate injection sites within the abdomen to avoid scar tissue buildup. Avoid the 2-inch zone around the navel. Standard insulin syringes (28 to 31 gauge, 6 to 8 mm needle length) work well. Allow the vial to reach room temperature before injecting to reduce discomfort.
Section 06
Cycling: What the Evidence Says
The cycling debate is one of the most contentious, misinformation-heavy topics in the tesamorelin community. Here is what is actually known versus community mythology.
| Claim | Source | Evidence Level |
|---|---|---|
| Must cycle to prevent GH desensitization | Forum extrapolation | Theoretical |
| Continuous use up to 52 weeks is documented | Phase III safety extension | Phase III Data |
| 5-on / 2-off is sufficient cycling | Community consensus | No Direct Evidence |
| Visceral fat reaccumulates within 12 weeks of stopping | Phase III follow-up | Documented |
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Claim
Source
Evidence Level
Section 07
Ready to Inject
0
Reconstitution steps required
503A
Licensed pharmacy (Optimal Balance), physician-supervised
Overnight
FedEx shipping in a reusable cooled travel case
Storage
Refrigerate at 2 to 8 degrees C (36 to 46 degrees F). Never freeze a reconstituted vial. Use within the Beyond Use Date printed on the label, per USP <797> sterile compounding standards.
Section 08
Lab Monitoring
Tesamorelin has a long human safety record under the Egrifta program, but lab monitoring still drives protocol decisions. IGF-1 is the primary biomarker. Fasting glucose and lipids are secondary panels.
IGF-1
Target: age-adjusted upper-normal quartile
The gold standard for tesamorelin efficacy. Drawn at baseline and at week 4 to confirm response. Ongoing every 90 days.
Fasting Glucose + Fasting Insulin + HbA1c
Fasting glucose under 100 mg/dL
Tesamorelin can mildly elevate fasting glucose in some patients. Important to monitor at baseline and every 90 days, particularly in patients with metabolic syndrome.
Triglycerides + LDL + HDL
Triglycerides under 150 mg/dL
Phase III data shows triglyceride improvement. Baseline panel establishes the response signal and rules out lipid-related contraindications.
ALT + AST + GGT
ALT under 35 U/L
Liver fat reduction is a documented secondary benefit. Monitor hepatic markers at baseline and every 90 days to track that signal.
Section 09
Stacking
Tesamorelin pairs well with non-GH-axis compounds and with TRT for men over 45. Stacking with other GH-axis compounds (HGH, MK-677) increases unpredictability without proportional benefit.
Pairs Well With
Ipamorelin
Different receptor (ghrelin) means complementary, not redundant, GH stimulation. Available as combo (Tesamorelin / Ipamorelin).
BPC-157
Tissue repair and gut healing. Complementary mechanism, no known interaction.
Optimized TRT
Tesamorelin layered onto established testosterone therapy is one of the highest-fit applications for men 45 plus targeting visceral fat.
MOTS-c
Mitochondrial peptide. Targets metabolic function via a different pathway.
Approach With Caution
Exogenous HGH
Combining GH secretagogue with exogenous GH causes supraphysiologic GH levels. Physician assessment required.
MK-677 (Ibutamoren)
Oral GH secretagogue. Can cause sustained GH elevation and insulin resistance when stacked.
Glucocorticoids
Suppress GH response. May blunt the IGF-1 signal of tesamorelin.
AOD-9604
Targets visceral and subcutaneous fat with a different mechanism. Overlap with tesamorelin produces unclear stacking benefit.
Section 10
Pricing
| Option | Medication Cost | Medical Cost | Notes |
|---|---|---|---|
| Brand-Name Egrifta (specialty pharmacy) | $3,000 to $6,000 per month range | Insurance and prescriber dependent | Branded finished form for HIV-associated lipodystrophy. Out-of-pocket cost without insurance is prohibitive for most off-label users. |
| Other Online Clinics | $300 to $500 per month | Visit and lab fees often bundled and not disclosed publicly | Per-cycle pricing varies. Verify all-in cost and lab inclusion before committing. |
| Optimal Balance Pharmacy + RxPepsDirect | $100 per 15 mg vial, paid to pharmacy | $39 visit fee, paid to RxPepsDirect | Pre-reconstituted, FedEx overnight. Labs billed separately by your chosen lab vendor. |
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Option
Medication Cost
Medical Cost
Notes
Who You Pay, and What For
Pharmacy: Medication
$100 per 15 mg vial. Compounded and shipped by Optimal Balance Pharmacy, a 503A licensed compounding pharmacy. Pre-reconstituted, FedEx overnight in a reusable cooled travel case.
Medical Service: Physician Consultation
$39 medical visit fee. Intake consultation, protocol design, prescription writing, and follow-up check-ins including IGF-1 and metabolic panel review. Billed by RxPepsDirect for the medical service only.
Section 11
Legal Access in 33 States
FDA-Approved Finished Form
Egrifta, branded by Theratechnologies
503A Compounded Available
Standard concentration only after 12/2024
Off-Label, Legal Practice
Standard and legal in U.S. medicine
High-Dose Compounded Removed
Tesamorelin 8 mg/mL no longer compoundable
Tesamorelin has an FDA-approved finished form (Egrifta) for HIV-associated lipodystrophy. Patient-specific compounding under Section 503A remains legal at the standard concentration. Tesamorelin High-Dose, the 8 mg/mL concentration that some clinics offered for extended protocols, was removed from the compoundable substances list in the December 2024 PCAC review. Standard-concentration tesamorelin remains available through licensed 503A pharmacies under a physician prescription.
Off-label prescribing is a standard, legal practice in U.S. medicine. Your prescribing physician will explain the regulatory status and evidence base for your specific protocol during your consultation.
Section 12
Community Q&A
Will tesamorelin shrink the belly fat I can see in the mirror?
Tesamorelin reduces visceral fat, the deep abdominal fat around your organs, not subcutaneous fat, the fat you can pinch. The visible mirror change is often subtle even when the metabolic benefit is significant. If your goal is purely aesthetic, you may not see a dramatic change.
How long until I see results?
Phase III clinical data shows measurable visceral fat reduction between weeks 8 and 16, with peak effect at 26 weeks. IGF-1 should be confirmable at week 4. Minimum useful protocol is 12 weeks. Full evaluation requires 26 weeks of consistent daily injection.
What happens when I stop?
Clinical data confirms visceral fat reaccumulates within approximately 12 weeks of discontinuation. Tesamorelin is a maintenance therapy. Plan accordingly.
Is tesamorelin safe long-term?
The Egrifta program documented continuous use up to 52 weeks without loss of effect or new safety signals. Glucose elevation is the most commonly reported lab finding, which is why your RxPepsDirect physician will review your metabolic panel during the protocol.
Why is my IGF-1 not moving?
If IGF-1 has not moved at week 4, your physician will evaluate dosing, adherence, sleep, thyroid function, and other variables. Roughly 31 percent of Phase III participants did not achieve the primary endpoint. Some patients are non-responders despite confirmed adherence.
Can I use tesamorelin with TRT?
Yes. Tesamorelin layered onto established testosterone therapy is one of the highest-fit clinical applications for men 45 plus targeting visceral fat. Your RxPepsDirect physician will review your existing TRT protocol at intake.
What happens if Optimal Balance Pharmacy is out of stock?
Pharmacy supply chains can fluctuate. If Optimal Balance is temporarily unable to fill your prescription, your RxPepsDirect physician will be notified and you will be contacted before any delay impacts your protocol. You only pay the pharmacy when your prescription actually ships.
Section 13
The RxPepsDirect Model
Tesamorelin is the only GHRH analog with Phase III trial data and an FDA approval. The Egrifta program established its safety profile across 52 weeks of continuous use. Within those limits, the visible mirror change is subtle, the non-responder rate is roughly 31 percent, and visceral fat reaccumulates when you stop. RxPepsDirect physicians will set realistic expectations based on your baseline IGF-1 and metabolic profile.
Pharmacy: Optimal Balance, 503A Licensed
Optimal Balance Pharmacy compounds your tesamorelin under a patient-specific prescription, USP <797> sterile standards, and federal 503A oversight. The pharmacy ships the medication directly to you and bills you for the medication.
Medical Service: RxPepsDirect Physicians
A licensed physician reviews your history, designs your protocol, writes your prescription, and reviews your IGF-1 plus metabolic panel data. RxPepsDirect bills the $39 medical visit fee for this service.
Transparent Safety Communication
The guide above flags the 31 percent non-responder rate, the subcutaneous vs visceral fat distinction, the reaccumulation timeline, and the High-Dose 503A removal. We do not hide limitations to make a sale.
Legal Access in 33 States
Every shipment is a compounded prescription medication filled by a 503A licensed pharmacy under a physician prescription. Tesamorelin has an FDA-approved finished form (Egrifta) and remains Category 1 compoundable at the standard concentration.
References
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010. PMID: 20101189
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010. PMID: 20554713
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. PMID: 25038357
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. PMID: 21668043
Related protocol guides
Other protocols in the same clinical territory. Each guide is co-bylined by a licensed RxPepsDirect prescriber.
GHRH analog (GRF 1-29)
Sermorelin protocol guide: pharmacology, dosing, IGF-1 monitoring, and the non-responder reality
The only GHRH analog still Category 1 compoundable. Daily injection, 6 to 12 month protocol, 30 to 40 percent non-responder rate, and IGF-1 the biomarker that decides the answer.
Growth hormone stack
CJC-1295 / Ipamorelin protocol guide: dosing, units-to-mcg, timelines, and the legal pathway
Pulsatility, DAC vs no-DAC, syringe math, the 90-day rule, gray-market purity data, and the 503A pathway. Written for the patient who wants the full picture.
Oral GH secretagogue (MK-677)
Ibutamoren (MK-677) guide: oral ghrelin receptor agonist, water retention, glucose elevation, WADA prohibition
The only oral GH secretagogue. Real GH and IGF-1 elevation. Real water retention. Real fasting-glucose drift. WADA prohibited. Monitoring is mandatory.
Continue reading